附属第三医院感染科,广东,广州,510630
网络首发:2020-11-20,
纸质出版:2020
移动端阅览
陈幼明, 郑丽花, 崇雨田, 等. 住院慢性乙型肝炎病毒感染者肝病谱构成比的变化分析[J]. 中山大学学报(医学科学版), 2020,41(6).
Analysis of the Changes of the Disease Spectrum of Patients with Chronic Hepatitis B Virus Infection[J]. Journal of Sun Yat-sen University (Medical Sciences), 2020, 41(6).
【目的】探讨抗病毒治疗以及治疗依从性对住院慢性乙型肝炎病毒(HBV)感染者肝病谱构成比的影响。【方法】回顾性收集2018 年在中山大学附属第三医院感染科住院的慢性HBV 感染者。根据患者入院前既往抗病毒治疗史,将纳入的患者分为抗病毒组(n = 460)和未抗病毒组(n = 1 240);根据患者的治疗依从性将抗病毒治疗的患者分为规范抗病毒组(n = 277)和不规范抗病毒组(n = 183)。分别比较两组的肝病谱构成比的分布情况。并与2011 年的研究结果进行比较。【结果】入院时抗病毒组中诊断为慢性乙型肝炎(CHB;中度)、CHB(重度)、慢加急性肝衰竭、肝硬化(代偿期)的比例显著低于未抗病毒组,差异有统计学意义(P < 0.01);而诊断为肝硬化(失代偿期)的患者比例高于未抗病毒组(70% vs. 37.1%,P < 0.001)。诊断CHB(中度)、CHB(重度)、慢加急性肝衰竭的比例在规范抗病毒组显著高于不规范抗病毒组,差异有统计学意义(P < 0.01),而规范抗病毒组的肝硬化(失代偿期)患者比例显著高于不规范抗病毒组,差异均有统计学意义(P < 0.001)。2011 年与 2018 年住院患者肝病谱构成比差异有统计学意义(P < 0.001)。相比 2011 年,2018 年诊断 CHB(中度)、CHB(重度)的患者比例有所下降(P < 0.05),而慢加急性肝衰竭的比例显著增高(11.8% vs. 16.9%,P < 0.001)。合并肝细胞癌的住院患者比例在2018 年显著高于2011 年(19.5% vs. 10.5%,P < 0.001)。2018 年住院患者此前接受抗病毒的比例高于 2011 年住院患者(27.1% vs. 17.2%,P < 0.001),不规范抗病毒的患者比例也显著高于 2011 年(P = 0.003)。【结论】抗病毒治疗可减少CHB 患者因肝炎活动而住院的比例,但不规范的抗病毒治疗增加了CHB(重度)、慢加急性肝衰竭患者的构成比。合并诊断原发性肝细胞癌的患者有增加趋势。
【Objective】To explore the effect of antiviral treatment and treatment adherence on the disease spectrum of patients with chronic hepatitis B virus(HBV)infection.【Methods】Data of patients with chronic HBV infection treated in the Department of Infectious Diseases of the Third Affiliated Hospital of Sun Yat-sen University in 2018 were retrospectively collected. According to the antiviral treatment history,the patients were divided into antiviral group(n = 460)and non-antiviral group(n = 1 240);according to the treatment adherence,the patients were divided into standard antiviral group(n = 277)and non-standard antiviral group(n = 183). The distribution of disease spectrum was compared between these two groups. Meanwhile,the differences of the proportion of disease spectrum were compared with previous data in 2011.【Results】The proportion of patients diagnosed as chronic hepatitis B(CHB)(moderate),CHB(severe),acute-on-chronic liver failure(ACLF)and cirrhosis(compensated stage)in antiviral group was significantly lower than that in non- antiviral group(P < 0.01),while the proportion of patients diagnosed as cirrhosis(decompensated stage)was higher than that in non-antiviral group(70% vs. 37.1%,P < 0.001). The proportion of CHB(moderate),CHB(severe)and ACLF in the standard antiviral group was significantly lower than that in the non-standard antiviral group(P < 0.01),and the proportion of patients diagnosed as cirrhosis(decompensated stage)in the standard antiviral group was significantly higher than that in the non- standard antiviral group(P < 0.001). There was a significant difference between the data of 2011 and those of 2018(P < 0.001). Compared with that in 2011,the proportion of patients diagnosed with CHB(moderate) and CHB(severe)decreased in 2018(P < 0.05),while the proportion of ACLF increased significantly(11.8% vs. 16.9%, P < 0.001). The proportion of hospitalized patients with hepatocellular carcinoma was significantly higher in 2018 than in 2011(19.5% vs. 10.5%,P < 0.001). In 2018,the proportion of inpatients who have received antiviral therapy was higher than that in 2011(27.1% vs. 17.2%,P < 0.001),and the proportion of patients who had poor adherence was significantly higher than that in 2011(P = 0.003).【Conclusions】Antiviral treatment can reduce the proportion of CHB patients hospitalized due to hepatitis activities,but the non-standard antiviral treatment increases the proportion of patients with CHB(severe)and ACLF. The number of patients with combined diagnosis of HCC is increasing.
0
浏览量
282
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
